Compare GSK plc (GSK) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Marqeta Inc — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while Marqeta Inc trades at $15.65 (market cap $1.62B). The key difference: GSK plc is far larger — about 63.3× Marqeta Inc's market cap, and GSK plc pays a 3.57% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| GSK | MQ | |
|---|---|---|
Market Cap | $102.60B | $1.62B |
Sector | Health | Technology |
52-Week High | $61.18 | $26.00 |
52-Week Low | $38.22 | $15.04 |
Enterprise Value | $123.04B | $935.36M |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Marqeta (MQ) trades at $15.62, up 0.13% with a bearish technical outlook. The company shows improving fundamentals with Q2 2026 revenue growth of 17% and second consecutive GAAP profitability. Recent partnerships with Google and Riskified highlight strategic expansion, while a 4:1 reverse stock split was completed in July 2026. Valuation remains elevated with a P/E of 173, though analyst consensus targets $19.00 with 32% buy ratings.
The outlook suggests cautious optimism as Marqeta transitions to profitability amid competitive fintech pressures. Key risks include execution on new initiatives and maintaining growth momentum. Upside potential exists if recent partnerships drive sustained revenue acceleration, but high valuation multiples require continued strong performance to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
